MedTrace Logo

N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients

NCT03492047 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2020-02-27

No results posted yet for this study

Summary

The purpose of the study is to evaluate the effect of N-acetyl cysteine in combination with paclitaxel on the clinical outcomes of patients with peripheral neuropathy, paclitaxel-induced peripheral neuropathy affect quality of life in cancer patients.

new therapeutic approches such as the antioxidant N-acetyl cysteine, showed to has neuroprotective effect, the aim of the study is to evaluate the effect of N- acetylcysteine(NAC) administration in the prevention of paclitaxel-Induced peripheral neuropathy.

Conditions

  • Peripheral Neuropathy Due to Chemotherapy

Interventions

DIETARY_SUPPLEMENT

low dose N-acetylcysteine

N-acetylcysteine 600mg twice daily

DIETARY_SUPPLEMENT

high dose N-acetylcysteine

N-acetylcysteine 1200mg twice daily

DRUG

Paclitaxel

Paclitaxel 80mg /m2 IV

Sponsors & Collaborators

  • Nasser Institute For Research and Treatment

    collaborator OTHER_GOV

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Hadeer G Khalefa, master · Nassar institute for research and treatment hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2019-04-01
Completion
2019-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03492047 on ClinicalTrials.gov